Stammdaten
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Unternehmen & Branche
| Name | Coeptis Therapeutics Holdings, Inc. |
|---|---|
| Ticker | COEP |
| CIK | 0001759186 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 6199 · Finance Services |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 57,6 Mio. USD |
| Beta | -0,43 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 1,363,045 | -11,917,015 | -2.81 | 16,153,921 | 13,561,994 |
| 2025-09-30 | 10-Q | 237,441 | -2,898,763 | -0.58 | 14,181,641 | 10,365,582 |
| 2025-06-30 | 10-Q | 200,681 | -4,334,586 | -1.17 | 12,191,479 | 6,095,830 |
| 2025-03-31 | 10-Q | 62,874 | -3,420,941 | -1.11 | 13,453,067 | 6,478,614 |
| 2024-12-31 | 10-K | 0 | -10,680,452 | -5.56 | 8,908,660 | 3,382,124 |
| 2024-09-30 | 10-Q | 0 | -1,828,914 | -0.05 | 8,955,984 | 4,824,733 |
| 2024-06-30 | 10-Q | 0 | -3,035,345 | -0.08 | 4,198,420 | -442,554 |
| 2024-03-31 | 10-Q | 0 | -3,001,388 | -0.08 | 9,394,321 | 4,359,365 |
| 2023-12-31 | 10-K | 0 | -21,266,537 | -16.56 | 4,571,089 | 813,964 |
| 2023-09-30 | 10-Q | 0 | -6,350,494 | -0.24 | 7,170,767 | 5,011,641 |
| 2023-06-30 | 10-Q | 0 | -3,202,620 | -0.15 | 7,155,699 | 2,489,627 |
| 2023-03-31 | 10-Q | 0 | -7,957,833 | -0.40 | 5,942,277 | 846,407 |
| 2022-12-31 | 10-K | 0 | -37,574,217 | -2.63 | 7,915,689 | 4,453,329 |
| 2022-09-30 | 10-Q | 0 | -5,648,709 | -0.42 | 33,299,182 | 6,743,355 |
| 2022-06-30 | 10-Q | 0 | -9,802,837 | -0.75 | 33,112,032 | 2,061,034 |
| 2022-03-31 | 10-Q | 0 | -19,179,693 | -1.52 | 75,982,365 | 2,337,195 |
| 2021-12-31 | 10-K | 75,000 | -13,449,280 | -1.23 | 6,765,576 | 2,350,634 |
| 2021-09-30 | 10-Q | 4,176,909 | 76,360,175 | -5,555,667 | ||
| 2021-06-30 | 10-Q | -1,803,758 | 76,446,235 | -9,730,666 | ||
| 2021-03-31 | 10-Q | 14,072,850 | 76,597,369 | -7,925,019 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.